US0327241065 - Common Stock
ANAPTYSBIO INC
NASDAQ:ANAB (4/24/2024, 3:53:31 PM)
After market: 19.27 0 (0%)19.27
+0.09 (+0.47%)
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 96 full-time employees. The company went IPO on 2017-01-26. The company is focused on developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases. Its product candidate pipeline includes Rosnilimab, which is designed to suppress aberrant T cell driven inflammation by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; ANB032, which is designed to augment BTLA signaling that is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; ANB033, which targets CD122, the common beta subunit shared by the IL-15 and IL-2 receptors; Imsidolimab, which inhibits the interleukin-36 receptor (IL-36R) and is developed for the treatment of generalized pustular psoriasis (GPP), and Etokimab, which inhibits IL-33 function and acts upstream of key cell types involved in atopy and the subsequent release of Th2 cytokines.
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121
P: 18583626295
CEO: Hamza Suria
Employees: 96
Website: https://www.anaptysbio.com/
/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
A powerfully bullish new analyst take on the company helped it rally on the market.
Here you can normally see the latest stock twits on ANAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: